ANGPTL4 and age-related macular degeneration: We observed an increase in the levels of ANGPTL4 in the aqueous fluid of patients who required injections every 4 weeks (i.e., patients who failed treatment extension) using the TEP/M protocol compared with non-AMD controls (Figure 1C).